Differences Between Responders And Non-Responders to Benralizumab
The response to benralizumab was defined, based on a similar definition using UAS7 in a previous study, as “no response” if at any time during the 16 weeks after the first benralizumab injection there was <40% improvement in UAS7, and as “response” if the UAS7 was ≤6.31 Seven (78%) of 9 subjects completing the study were thus classified as responders; among them five were complete responders (i.e., no hives at visits 5 or 6). Between responders and non-responders, their age difference (51.6 vs. 53, p=0.9) and the duration of disease (5 vs. 9 years, p=0.5) were not statistically significant. The adjusted mean UAS7 percentage difference from Visit 1 till Visit 5 was -84% for responders and +7.5% for non-responders, p=0.0009 (S-Table 3) . These differences were adjusted for the length of disease, subject age, and peripheral blood eosinophil percentages (eos%). Although there were no significant differences for UAS7 at baseline between responders versus non-responders (ΔUAS7= -3.4, p=0.9), there were significant differences observed at visit 5 (ΔUAS7= -30.4, p=0.03). The average length of disease between responders and non-responders was 5.1 vs. 9.0 years, p=0.06. Interestingly, there were significant differences between responders and non-responders at baseline (visit 1) for peripheral blood eos% (-6±1, p=0.001) and basophil% (-1.2±0.2, p=0.02), which were not observed at visit 5 (eos%: 0±1, p=0.9; basophil%: 0.2±0.2, p=0.8) (S-Table 3 ).